Genetic Cardiomyopathies Market Outlook:
Genetic Cardiomyopathies Market size was over USD 2.51 billion in 2025 and is projected to reach USD 8.67 billion by 2035, witnessing around 13.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of genetic cardiomyopathies is evaluated at USD 2.81 billion.
The growth of the market can be attributed to the increasing instances of genetic cardiomyopathies. There were over 2 million instances of myocarditis, nearly 1.6 million cases of arrhythmogenic cardiomyopathy, and approximately 4 million cases of other cardiomyopathy worldwide. Genetics has played a significant part in the identification of various cardiomyopathies, and the area of heart failure (HF) genetics is quickly expanding.
In addition to these, factors that are believed to fuel the growth of genetic cardiomyopathies market are the approval of new drugs for effective treatment. The Food and Drug Administration (FDA) granted the novel treatment, known as Camzyos, breakthrough therapy and orphan drug designations in April. Patients with obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association class II-III are eligible for treatment to enhance exercise capacity and symptoms. Patients raved about how it improved their quality of life by reducing symptoms such as palpitations, shortness of breath, leg oedema, and diminished exercise ability. Mavacamten minimizes the likelihood that these patients will require a more substantial treatment, such as septal myectomy, an open heart surgery that eliminates a portion of the thickened septum, or alcohol septal ablation.
